High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis

Denosumab is a fully human monoclonal antibody against the receptor activator of nuclear factor-κB ligand (RANKL) that is used for the treatment of osteoporosis. Denosumab-induced hypocalcemia is a rare but important adverse event, which is usually asymptomatic in patients with osteoporosis. It is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Koji, Nagai, Takashi, Tsuchiya, Koki, Oshita, Yusuke, Kuroda, Takuma, Ito, Hiroshi, Tani, Soji, Dodo, Yusuke, Toyone, Tomoaki, Inagaki, Katsunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183698/
https://www.ncbi.nlm.nih.gov/pubmed/30349211
http://dx.doi.org/10.2147/CIA.S180614

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183698/
https://www.ncbi.nlm.nih.gov/pubmed/30349211
http://dx.doi.org/10.2147/CIA.S180614

Ejemplares similares